Mackenzie Financial Corp Has $55.74 Million Stake in Humana Inc. (NYSE:HUM)

Mackenzie Financial Corp boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 75.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,746 shares of the insurance provider's stock after purchasing an additional 52,469 shares during the period. Mackenzie Financial Corp owned approximately 0.10% of Humana worth $55,737,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Dakota Wealth Management boosted its stake in shares of Humana by 27.4% during the 4th quarter. Dakota Wealth Management now owns 7,555 shares of the insurance provider's stock worth $3,459,000 after acquiring an additional 1,624 shares in the last quarter. Strs Ohio boosted its position in shares of Humana by 29.2% in the 4th quarter. Strs Ohio now owns 108,393 shares of the insurance provider's stock valued at $49,623,000 after purchasing an additional 24,511 shares during the period. Vontobel Holding Ltd. increased its stake in Humana by 18.1% in the 4th quarter. Vontobel Holding Ltd. now owns 25,524 shares of the insurance provider's stock worth $11,685,000 after purchasing an additional 3,910 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in Humana by 3.7% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 365,115 shares of the insurance provider's stock worth $167,153,000 after buying an additional 13,067 shares during the period. Finally, Lecap Asset Management Ltd. purchased a new stake in Humana during the fourth quarter valued at about $2,808,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Up 1.9 %

NYSE HUM traded up $5.94 during trading on Wednesday, hitting $323.46. 1,956,514 shares of the company traded hands, compared to its average volume of 2,015,295. The company has a market capitalization of $39.03 billion, a P/E ratio of 16.02, a PEG ratio of 1.84 and a beta of 0.45. Humana Inc. has a 12 month low of $299.23 and a 12 month high of $541.21. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. The business has a fifty day simple moving average of $345.31 and a 200 day simple moving average of $426.43.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The business had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The company's revenue for the quarter was up 17.9% on a year-over-year basis. As a group, sell-side analysts predict that Humana Inc. will post 16.06 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be given a $0.885 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.54 annualized dividend and a dividend yield of 1.09%. Humana's dividend payout ratio is 17.86%.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of the firm's stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company's stock, valued at approximately $946,358.02. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Oppenheimer restated an "outperform" rating and issued a $630.00 price target on shares of Humana in a research report on Wednesday, January 17th. TheStreet downgraded Humana from a "b" rating to a "c+" rating in a report on Monday, January 8th. Argus lowered Humana from a "buy" rating to a "hold" rating in a research report on Wednesday, March 13th. Royal Bank of Canada decreased their price objective on Humana from $507.00 to $415.00 and set an "outperform" rating for the company in a research report on Friday, January 26th. Finally, Mizuho dropped their target price on Humana from $550.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, January 26th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $465.42.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.